AMD

The study, published in PLoS Genetics, examined how glucose metabolism affects gene expression in light-sensing photoreceptors.

Researchers noted growing evidence supporting an additional role for B vitamins.

The analysis included 12,183,254 patients, with 304,823 identified as smokers and 11,878,431 as non-smokers.

Phase 2 ArMaDa data show statistically significant 31% reduction in geographic atrophy lesion growth with OCU410 at 12 months, with a favorable safety profile supporting phase 3 development.

Metformin, a common diabetes medication, may be associated with less development of intermediate age-related macular degeneration (AMD).

In recent months, developments have ranged from regulatory setbacks to real-world data releases.

The prospective observational study is being conducted across 18 countries.

The goal of the study was to investigate the natural history of macular tissue preservation in GA by evaluating the relationship between the MTII and BCVA over time.

A total of 38 patients were included in the study. All underwent implantation of the PRIMA retinal prosthetic chip with the goal of restoring vision.

Understanding AMD pathophysiology through nutrition has helped shape the disease’s detection and management.

Knowing what’s on the market for AMD and GA aids in preserving vision.

The FDA issued a CRL for ONS-5010, citing the need for additional confirmatory efficacy evidence despite previous trials showing efficacy, according to the company.

Additionally, the FDA approved a monthly dosing option for some patients who may benefit from resuming this schedule across approved indications.

Outlook Therapeutics seeks FDA clarity on ONS-5010 after a complete response letter, aiming to address efficacy concerns for wet AMD treatment.

FDA issues a complete response letter to Outlook Therapeutics for ONS-5010, citing insufficient evidence of effectiveness for wet AMD treatment.

Nutrition is not ancillary to eye health—it is foundational.

Diagnostic tools, therapeutic innovations such as anti-vascular endothelial growth factor (VEGF) therapies, and supportive technologies to manage vision loss form the myopic macular degeneration market.

Additionally, the company is exploring different strategic alternative to advance its suprachoroidal space (SCS) platform and drug development pipeline.

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

The campaign provides tools to patients, researchers, clinicians, industry, and advocates with tools to tell their stories that advocate for vision research.

From blue light blockers to sleep apnea, Jacqueline Theis, OD, FAAO, FNAP; and Joseph Allen, OD, FAAO, Dipl ABO, outlined how sleep can influence brain and ocular health, and vice versa.

A study reveals a genetic link between instant coffee consumption and increased risk of dry age-related macular degeneration, urging caution for high-risk individuals.

deepeye TPS is designed to close the gap between real-world outcomes and trial data by reducing patient dropout.

Valeda met the primary end point in the US LIGHTSIDE III trial, improving the best corrected visual acuity in patients for 24 months of >5 letters or equivalent to 1 line improvement on the eye chart, according to the company.

The trial assesses GAL-101 as an oral therapy designed to treat Alzheimer disease, dry age-related macular degeneration, and glaucoma.